Bioteque (ROCO:4107) Operating Income: NT$721 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4107 Bioteque Corp ROCO:4107
86 GF Score
Price NT$114.00
GF Value NT$130.61
Valuation Modestly Undervalued
View Full Analysis

What is Bioteque Operating Income?

Bioteque ROCO:4107 86 Operating Income is NT$721 Mil as of Jun. 2026. GuruFocus rates ROCO:4107 with a GF Score™ of 86/100 and a GF Value™ of NT$130.61 (Modestly Undervalued).

Bioteque's Operating Income for the three months ended in Jun. 2026 was NT$196 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$721 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Bioteque's Operating Income for the three months ended in Jun. 2026 was NT$196 Mil. Bioteque's Revenue for the three months ended in Jun. 2026 was NT$588 Mil. Therefore, Bioteque's Operating Margin % for the quarter that ended in Jun. 2026 was 33.35%.

Good Sign:

Bioteque Corp operating margin is expanding. Margin expansion is usually a good sign.

Bioteque's 5-Year average Growth Rate for Operating Margin % was 0.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioteque's annualized ROC % for the quarter that ended in Jun. 2026 was 23.74%. Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 34.53%.


Bioteque  (ROCO:4107) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioteque's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=784.556 * ( 1 - 23.28% )/( (2555.406 + 2515.533)/ 2 )
=601.9113632/2535.4695
=23.74 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4805.862 - 765.568 - ( 1797.314 - max(0, 972.549 - 2457.437+1797.314))
=2555.406

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4881.033 - 738.886 - ( 1870.897 - max(0, 931.18 - 2557.794+1870.897))
=2515.533

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=799.848/( ( (2328.701 + max(-262.167, 0)) + (2303.846 + max(-192.585, 0)) )/ 2 )
=799.848/( ( 2328.701 + 2303.846 )/ 2 )
=799.848/2316.2735
=34.53 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(218.121 + 299.839 + 47.369) - (765.568 + 0 + 61.928)
=-262.167

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(229.646 + 311.923 + 52.542) - (738.886 + 0 + 47.81)
=-192.585

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Bioteque's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=196.139/588.198
=33.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Bioteque Operating Income Related Terms


Bioteque Operating Income Historical Data

* Premium members only.

The historical data trend for Bioteque's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque Operating Income Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 547.93 578.38 580.18 643.17 670.28

Bioteque Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 162.41 168.42 180.34 176.01 196.14
ROCO:4107
86GF Score
Bioteque Corp ROCO:4107
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioteque Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$721 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of NT$721 Mil mean?
Bioteque (ROCO:4107) has a Operating Income of NT$721 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Bioteque and its competitors.
Is Bioteque's Operating Income too high?
Bioteque's current Operating Income is NT$721 Mil. Overall, Bioteque has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's Operating Income compare to ISRG and BDX?
Bioteque's Operating Income of NT$721 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Bioteque and its competitors. Bioteque's current Operating Income is NT$721 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.61, compared to a current price of NT$114.00 — trading 12.7% below its estimated fair value. The current Operating Income is NT$721 Mil. Bioteque's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current Operating Income is NT$721 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$114.00 is trading 12.7% below its estimated GF Value™ of NT$130.61. GuruFocus considers Bioteque to be Modestly Undervalued.

Key valuation signals for ROCO:4107:

  • Operating Income: NT$721 Mil
  • GF Value™: NT$130.61 vs. price of NT$114.00 (12.7% below fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
86GF Score

Get the complete analysis for ROCO:4107

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$114.00
Price
NT$130.61
GF Value